The Nasdaq faces the last leg of the year at all-time highs driven by the better economic outlook following advances in anti-Covid vaccines and the presidential results in the United States .
The US indicator, the main benchmark for the technology sector on the Wall Street stock market, registered an increase of over 33%, the best performance among the main stock markets in New York. This Monday, the Nasdaq secured 12,500 points, its greatest historical barrier, surpassed for the first time throughout the session last Friday.
The effect of Pfizer and Moderna
The great drivers of generalized growth in world markets, the advances reported by the pharmaceutical companies Pfizer and Moderna, take the selective to its highest level.
“Despite the logistical challenges, it will be seen as a great step to get the economy back on track,” eToro analysts note in a comment. From the broker they also value the “positive” news in the progress of the negotiations for the fiscal stimulus package, which would amount to 908,000 million dollars according to the proposal of the Democratic senators.
In the last month, Pfizer appreciated more than 13% to its current price, more than $ 41 per share, after reporting the highest efficacy in its vaccine, of 95%. The advice of the analysts of the Bloomberg panel is, however, to maintain positions, with 16 recommendations, 72% of the total.
Moderna, for its part, has risen by 141% since the beginning of November. Despite being less efficient than Pfizer (90%), lower logistical challenges also push the company to all-time highs, at more than $ 162.8 per share.
Tesla, over $ 630
The electric vehicle giant Tesla is another one that is also shooting towards its all-time highs, surpassing $ 630 per share. In the year, Elon Musk’s company revalued about 700%, while this Monday it boosted above 5%. The reason for the rise is, in addition to following the wake of the markets, the forecast that it could exceed its target of 500,000 deliveries by the end of the year.
The purchase recommendations of the Bloomberg panel surpass the rest after the latest revisions, with 16 compared to 12 to maintain and 13 sales. In the next twelve months, its share price would be similar to the current one, of $ 628 per share.
